Altrenogest affects expression of galectin-3 and fibroblast growth factor 9 in the reproductive tract of sows. Issue 5 (1st October 2021)

• Record Type: Journal Article
• Authors: Baek, Sun-Young; Sa, Soo-Jin; Jeong, Young-Dae; Cho, Eun-Seuk; Hong, Jun-Gi; KIm, Young-Shin; Cho, Kyu-Ho-; Park, Seol-Hwa; Kim, Kyung-Woon; Lee, Hwi-Cheul; Hochi, Shinichi; Lee, Seunghwan; Choi, Inchul; Chung, Hak-Jae
• Is Part Of: Animal biotechnology. Volume 32:Issue 5(2021)
• Page Start: 537
• Page End: 543
• Publication Date: 2021-10-01
• Subjects: Altrenogest -- endometrial receptivity -- galectin-3 -- FGF9 -- swine reproduction; Animal biotechnology -- Periodicals; Animals, Domestic -- genetics -- Periodicals; Animals, Genetically Modified -- Periodicals; 660.6
• DOI: 10.1080/10495398.2020.1726362
• Languages: English
• ISSNs: 1049-5398

Abstract

Abstract: A synthetic progestin altrenogest (ALT) is used to synchronize the estrus cycle of swine for fixed-time artificial insemination (AI) and has been shown to improve follicular development and reproductive performances in post-weaning sows. However, the effects of ALT treatment on reproductive tracts, including the ovaries, oviducts and uterus have not been yet clarified. In this study, we examined the expression of genes involved in endometrial responses in ALT-treated sows. ALT did not significantly alter luteinizing hormone (LH), follicle-stimulating hormone (FSH) and estradiol profiles in blood compared to untreated control. Quantitative RT-polymerase chain reaction (qRT-PCR) analysis showed that the expression of genes encoding galectin-3 ( LGALS3 ) and fibroblast growth factor 9 ( FGF9 ) was upregulated in the reproductive tracts of ALT-treated sows, including the ovaries, oviducts and uteri. Moreover, ALT treatment induced the expression of FGF9 and galectin-3 proteins, and promoted their localization to the luminal epithelium of the oviducts and uterus. Our findings suggest that the enhancement of reproductive performance shown by ALT-treated sows is associated with the upregulation of galectin-3 and FGF9, which are essential for endometrial receptivity, successful implantation, and pregnancy.